Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The endometriosis market was valued at USD 727.58 Million in 2025. It is poised to grow at a CAGR of 5.21% during the forecast period of 2026-2035, and reach USD 1209.07 Million by 2035. The rising prevalence of endometriosis, increasing awareness, and delayed diagnosis are driving demand. Advancements in hormonal therapies, improved diagnostic methods, and growing investments in women’s health further support market growth.
Geopolitical Impact of Iran, US, and Israel War on the Endometriosis Market
United States: The Endometriosis Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. 31 force majeure declarations by polymer suppliers, polypropylene and polyethylene price spikes, and chemical manufacturer surcharges of up to 30% are flowing through supply chains. U.S. consumer inflation is projected at 4.2% for 2026, above pre-war forecasts, with fuel costs above USD 4 per gallon compressing household discretionary budgets. Retail supply chains are absorbing the combined impact of 30% higher freight costs, 15-20% packaging material inflation, and rising transport fuel costs, compressing retailer margins. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets.
Iran: Iran's domestic Endometriosis sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.
Israel: Israel's Endometriosis sector is experiencing near-term disruption from wartime conditions. Consumer spending on non-essential categories has declined as millions of Israelis regularly shelter from missile and drone alerts. Supply chain logistics are disrupted by regional airspace closures, elevated war-risk insurance premiums, and the suspension of major carrier services through the region. International business partnerships with Israeli companies have been temporarily suspended. Post-conflict reconstruction and recovery demand is expected to provide meaningful demand acceleration across affected market segments once operational conditions normalise.
Government
Market
Procurement
In March 2026, research highlights precision medicine approaches for endometriosis, targeting individual disease biology to develop personalized therapies, potentially improving symptom management and patient outcomes.
In March 2026, EndoCyclic Therapeutics announced FDA clearance of its Investigational New Drug (IND) application for ENDO‑205, a first‑in‑class non‑hormonal precision peptide therapeutic for endometriosis. This suggests an important step toward clinical trials of a novel treatment modality beyond hormone suppression.
In December 2025, Hope Medicine’s HMI-115 received FDA Fast Track designation for treating moderate-to-severe endometriosis pain. The monoclonal antibody showed strong Phase II results, significantly reducing pain while maintaining hormonal balance, highlighting a promising non-hormonal treatment pipeline.
Endometriosis is a chronic gynecological condition characterized by the growth of endometrial-like tissue outside the uterus, causing pain and infertility. The market is driven by rising disease prevalence, increasing awareness, and improved diagnostic techniques. Advancements in hormonal therapies and minimally invasive surgeries are enhancing treatment outcomes. Growing research investments and focus on women’s health are further supporting market expansion. The market reached a value of approximately USD 727.58 Million in 2025.
Rising FDA Clearance Driving the Endometriosis Market Expansion
The shift toward non-hormonal treatments is a key market driver. For instance, in January 2026, EndoCyclic Therapeutics received FDA clearance for its IND application for ENDO‑205, a first-in-class peptide therapy targeting endometriotic lesions. This innovation is expected to reduce reliance on invasive procedures, alleviate pelvic pain, and expand patient access, supporting sustainable growth in the treatment market.
Key trends shaping the market include personalized therapies, non-hormonal treatments, precision medicine, improved symptom management, reduced laparoscopic surgery, and enhanced patient outcomes.
Increasing Precision Medicine Approaches Shaping the Market Landscape
The growing focus on personalized therapies is driving endometriosis market trends. For instance, in March 2026, researchers at Yale School of Medicine (YSM) highlighted precision medicine approaches targeting individual patient biology. This strategy could reduce reliance on traditional hormonal therapy and invasive interventions like laparoscopic surgery, improve outcomes for patients with pelvic pain, and signal strong future growth in endometriosis treatment.
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Treatment Type
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Hormone Therapy Expected to Lead the Market Segment by Treatment Type
The hormone therapy segment accounted for the largest share, exceeding 79% during the historical period, supported by its effectiveness in managing symptoms and slowing disease progression. Increasing clinical preference for targeted treatments and long-term management approaches continues to drive adoption. The use of hormonal therapy remains central to treatment strategies, ensuring sustained market dominance and improved patient outcomes.
The United States held a dominant share of approximately 37% during the historical period, driven by advanced healthcare infrastructure and higher diagnosis rates. Strong awareness initiatives and access to specialized care contribute to early intervention and treatment uptake. Increasing focus on managing pelvic pain associated with endometriosis further supports market growth, alongside continuous innovation in therapeutic solutions and patient care delivery.
The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bayer AG, headquartered in Leverkusen, Germany, was established in 1863. The company has a strong presence in women’s health, offering therapies for gynecological conditions. Its portfolio includes dienogest-based treatments widely used for endometriosis management, addressing symptoms such as pain and lesion progression through targeted hormonal approaches and long-term disease control strategies.
Pfizer Inc., headquartered in New York, United States, was founded in 1849. The company focuses on innovative therapeutics across multiple disease areas, including women’s health. Its portfolio includes treatments supporting anti-inflammatory treatment approaches and pain management solutions, contributing to improved symptom relief and quality of life in patients with endometriosis and related conditions.
AbbVie Inc., headquartered in North Chicago, United States, was established in 2013. The company is a key player in endometriosis treatment, particularly through its focus on advanced hormonal therapies. Its portfolio includes elagolix, an oral GnRH antagonist designed to manage moderate to severe pain, offering a non-surgical option for effective symptom control.
AstraZeneca, headquartered in Cambridge, United Kingdom, was founded in 1999. The company emphasizes innovation in reproductive and chronic disease management. While not a primary endometriosis-focused player, its broader portfolio supports treatments addressing pelvic pain and inflammatory pathways, contributing to improved therapeutic outcomes in women’s health and related disorders.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market are ObsEva, Teva Pharmaceuticals, Astellas Pharma Inc., and Eli Lilly and Company.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Treatment Type |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.